Molecular imaging demonstrates promise for predicting complete pathologic response in HER2-positive breast cancer

Health ~5 min read ▶ 5 min 49 s listen
Colonel Reyes Colonel Reyes Hutch Hutch

In short

Molecular imaging promises to predict complete remission in HER2-positive breast cancer, potentially sparing women unnecessary chemotherapy. However, the hosts debate whether scans should replace traditional biopsies, highlighting concerns about false negatives versus overtreatment and the need for validated accuracy data.

One idea raised: Considering the patient's well-being and quality of life alongside established protocols can help balance the desire for faster results with the need for rigorous verification.

0:0005:49

Keep your appetite for life as well as your appetite for dinner.

Lines worth sharing

Each one is a ready picture: share the link and it appears as a card in the feed, or save the image. Cards marked ▶ Video also come as a short clip with music: tap to watch, then save or share it.

Colonel ReyesHey, quick one before we move on - Molecular imaging demonstrates promise for predicting complete pathologic response in HER2-positive breast cancer. What's your first thought?

HutchMy first thought is that this could spare a woman weeks of grueling chemo if her tumor is shrinking faster than expected. Right now, we wait months to see if surgery will show a full remission, but if a scan can flag that early, maybe she gets to stop taking drugs that wreck her immune system while she still needs it strong. Sure, worked great on paper until we confirm it holds up in real clinics.

Colonel ReyesSomething about that explanation feels too easy.

HutchWait, really? You’re saying a scan done mid-treatment beats waiting for the surgeon’s report? That’s the kind of thing that saves a woman’s body from unnecessary radiation. The whole point isn’t whether the protocol looks tidy; it’s whether she walks out of that hospital room without getting sick again.

Colonel ReyesPicture a patient whose scans look clear after cycle three, so the team pulls the plug on maintenance therapy to save her quality of life. Six weeks later, pathology reveals microscopic cells hiding where the image couldn't resolve, meaning the "early" win was actually a false negative that cost us time. We don't get to skip verification steps just because the result felt reassuring at the moment; the procedure has to prove itself safe before anyone trusts it over the biopsy knife.

HutchPicture someone who finishes four rounds of treatment and the PET scan comes back totally clean, letting her go home to plan her wedding instead of sitting in another infusion chair for six more weeks. If that clear scan turns out right ninety percent of the time, accepting a ten percent risk of lingering micro-cells beats forcing every single patient through the same brutal schedule regardless of how their body responded.

Colonel ReyesNinety percent accuracy isn't good enough when the remaining ten are living women. You can't gamble with human lives based on an unverified statistic. Prove the margin of error first.

HutchHe’s right that we can’t let a ten percent miss rate slide, but holding every patient hostage to that uncertainty means some are getting extra cycles they simply do not need. The scan gives us a live readout during treatment, whereas the final pathology report only tells us what happened after the damage is already done. We need better resolution data before we trust it blindly, but ignoring the tool entirely guarantees we keep overtreat ing everyone by default.

Colonel Reyesis absolutely correct that the current model forces unnecessary toxicity on responders who should be spared, yet he keeps referring to an accuracy figure that hasn’t been published anywhere near the article context provided here. Without validated sensitivity metrics specifically for ⁶⁸Ga-HER2 PET/CT against pathological truth, we are debating a capability that exists only in theoretical projection rather than clinical reality.

HutchYou're arguing about a map that doesn't exist yet, which is like judging a car engine before the factory even pours the concrete. The scan offers something no pathology report does: a chance to adjust course while there's still road left to drive. Until those validation numbers hit print, we're both guessing, but at least my guess points toward saving her body from six more weeks of poison.

Colonel ReyesConsider the oncologist who signs off on stopping maintenance therapy based solely on a preliminary image, bypassing the mandatory multidisciplinary review board. That doctor carries personal liability for a decision made outside established protocols, turning a potential diagnostic breakthrough into a career-ending malpractice suit before the science is ever settled.

HutchLiability only matters if she comes back with cancer. Right now, the only thing carrying real weight is her survival, not your legal checklist.

Colonel ReyesSurvival without protocol is just luck wearing a lab coat. If she relapses because the board never reviewed the case, her family will file suit citing exactly the procedural gap you’re waving away today. The law demands documented oversight, not heroic improvisation.

HutchYour legal checklist protects the hospital's wallet, not the woman standing in front of them. She gets to choose whether to stop the chemo; the lawsuit follows later if things go sideways, but she won't get those six weeks back if we force her through them anyway. Sure, worked great on paper.

Colonel ReyesHer choice is valid, but exercising it without the safety net of a formal review converts a medical preference into a legal vacuum. We aren't banning the scan; we are demanding the documentation that proves the risk was calculated, not improvised. Procedure isn't red tape, it's the difference between informed consent and blind faith.

HutchInformed consent means she understands the trade-off, not that she waits for a committee stamp while the tumor shrinks or grows. You want the paperwork to prove the risk was weighed? Fine, but weigh it fast enough that the result still saves her life, not just clears the audit trail. Sure, worked great on paper, until the patient dies waiting for the signature.

Colonel ReyesSpeed is not a substitute for verification, and rushing the board creates a precedent where subjective speed trumps objective data. We cannot treat unvalidated molecular signals as definitive proof when the standard of care relies on confirmed pathological response. Until that independent review confirms the scan’s accuracy, the patient remains exposed to a risk that has never been properly quantified.

Read next

Dialogues on the same topic

If this one stuck with you

A different subject, but the same kind of feeling

Other dialogues in Health

See all in this world →